Notice of Results and Investor Presentation

RNS Number : 9334U

Destiny Pharma PLC

03 April 2023

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Notice of Full Year Results and Investor Presentation

Brighton, United Kingdom - 30 March 2023  - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, will announce its financial results for the year ended 31 December 2022, on Thursday 13 April 2023.

Neil Clark, Chief Executive Officer and Shaun Claydon, Chief Financial Officer, will provide a live presentation on the same day, at 10:30 am BST, followed by a Q&A session accessible via the Investor Meet Company platform.

The presentation is open to analysts and all existing and potential new shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00 am BST the day before the meeting, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma plc via:  https://www.investormeetcompany.com/destiny-pharma-plc/register-investor

Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
[phone]
[e-mail]

Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
[phone]
[e-mail]

finnCap Ltd  (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
[phone]

Shore Capital  (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

MC Services AG
Anne Hennecke / Andreas Burckhardt
[phone]

Stern IR - US

Janhavi Mohite

[phone]

[e-mail]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV^TM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the company, please visit  www.destinypharma.com

 

END

 

 

NORUAUWROSUOORR